treatment group

[키워드] acting Acute respiratory failure acutely ill patient acutely ill patients addition Admission age allergy anamnesis antiretroviral Antiviral Antiviral treatment approach ARMS assigned Asthma Autoimmune disease AVPU being binding antibody Blinding block blocks blood pressure blood sample bridge calculated Care cartridge Chemotherapy chronic kidney diseases clinical assessment Clinical Center clinical centers Clinical deterioration clinical monitoring Clinical sign conducted Control control arm control group control patients Controlled COVID-19 COVID-19 symptoms crackles creatinine criteria cytokine Darmstadt Day death Dementia determined by diagnosed disease Disease progression dissemination dose Efficacy EGFR Elderly patient element eligible Eligible patients Endpoint enrolled enrolment EudraCT evaluate Evidence evidence of exclusion criteria expected experimental arm female following form Gender Germany Health heart rate High-dose HIV infection Hospitalized hospitalized patients hypersensitivity ICU identification number IFN IFN-β IFNβ immunomodulation immunomodulatory immunomodulatory property immunosuppressive Impaired impairing inclusion criteria increase in Infectious disease Infectious diseases Informed consent injected injection intensive care unit interferon Interferon-beta investigator involved kidney laboratory-confirmed SARS-CoV-2 infection Lazzaro Spallanzani less level of care Life expectancy low-dose male management mechanical ventilation mild COVID-19 symptom mild COVID-19 symptoms multiple sclerosis Nasopharyngeal swab nasopharyngeal swabs National Early Warning Score NEWS2 non-hospitalized patients normal range number objective Older open Open-label outcome oxygen oxygen saturation participant Patient patient identification patients patients treated PCR performed phase physical physician Presence primary endpoint proportion protocol provide Psychological pulse rales randomised randomised controlled trial randomization randomization system Randomized Randomly receive recruitment reducing reduction in Regional registration date relapsing renal function Respiratory failure respiratory rate responsible resulting risk Rome room air RT-PCR Sample size SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 RT-PCR score Secondary objective Secondary objectives selected sequence severe COVID-19 severe depression severe disease specimen SpO2 Standard of care status stratified Stratified randomization Study protocol subcutaneously subject supervision supplemental oxygen supplementary material symptomatic temperature Toxicity treat Treatment treatment arm treatment group Trial Trial registration unique unit venous venous blood Version vital signs website Withdrawal worsening written Informed Consent
[DOI] 10.1186/s13063-021-05367-6 PMC 바로가기 [Article Type] Letter